See more : AstraZeneca PLC (AZNCF) Income Statement Analysis – Financial Results
Complete financial analysis of Aeglea BioTherapeutics, Inc. (AGLE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aeglea BioTherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Orange Sky Golden Harvest Entertainment (Holdings) Limited (1132.HK) Income Statement Analysis – Financial Results
- Sulja Bros Building Supplies Ltd. (SLJB) Income Statement Analysis – Financial Results
- SuperCopper (CUPR.CN) Income Statement Analysis – Financial Results
- KLX Energy Services Holdings, Inc. (KLXE) Income Statement Analysis – Financial Results
- Oneview Healthcare PLC (ONE.AX) Income Statement Analysis – Financial Results
Aeglea BioTherapeutics, Inc. (AGLE)
About Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 58.58M | 57.07M | 59.64M | 64.60M | 36.72M | 22.82M | 18.14M | 11.45M | 6.83M |
| General & Administrative | 28.53M | 27.32M | 21.84M | 15.73M | 12.63M | 10.07M | 8.39M | 5.95M | 2.07M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.53M | 27.32M | 21.84M | 15.73M | 12.63M | 10.07M | 8.39M | 5.95M | 2.07M |
| Other Expenses | -7.00K | -122.00K | -5.00K | -63.00K | -57.00K | -42.00K | -36.00K | -2.00K | 0.00 |
| Operating Expenses | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Cost & Expenses | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Interest Income | 837.00K | 111.00K | 593.00K | 2.14M | 1.17M | 482.00K | 244.00K | 22.00K | 1.00K |
| Interest Expense | 837.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.57M | 1.58M | 996.00K | 418.00K | 293.00K | 249.00K | 132.00K | 89.00K | 19.00K |
| EBITDA | -84.78M | -65.65M | -80.49M | -80.33M | -44.06M | -27.68M | -21.77M | -11.23M | -7.44M |
| EBITDA Ratio | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,133.10% | -531.72% | -470.48% | -184.49% | 0.00% |
| Operating Income | -84.78M | -65.65M | -81.48M | -80.33M | -45.46M | -27.68M | -21.91M | -11.32M | -8.90M |
| Operating Income Ratio | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,169.32% | -531.72% | -473.34% | -185.95% | 0.00% |
| Total Other Income/Expenses | 830.00K | -11.00K | 588.00K | 2.08M | -57.00K | -42.00K | -36.00K | 20.00K | -1.44M |
| Income Before Tax | -83.95M | -65.66M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Income Before Tax Ratio | -3,604.59% | -350.39% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| Income Tax Expense | -136.00K | 141.00K | -593.00K | -2.56M | -57.00K | -731.00K | -244.00K | -22.00K | 1.44M |
| Net Income | -83.82M | -65.80M | -80.30M | -75.69M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Net Income Ratio | -3,598.75% | -351.14% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| EPS | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.40 | -24.71 | -37.93 |
| EPS Diluted | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.40 | -24.71 | -37.93 |
| Weighted Avg Shares Out | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 272.80K |
| Weighted Avg Shares Out (Dil) | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 272.80K |
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle, DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside industry veterans Jeffrey Albers and Laurie Stelzer Management...
Aeglea BioTherapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , Nov. 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent...
Aeglea BioTherapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , Nov. 3, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Aeglea BioTherapeutics (NASDAQ: AGLE)
NEW YORK , Nov. 1, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) on behalf of the company's shareholders. The investigation seeks to determine whether Aeglea's directors breached their fiduciary duties...
Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences
WALTHAM, Mass. , Oct. 30, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will...
Aeglea BioTherapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that, Aeglea's independent...
Aeglea BioTherapeutics to Participate in Upcoming September Conference
WALTHAM, Mass. , Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate...
Aeglea BioTherapeutics Announces Reverse Stock Split
WALTHAM, Mass. , Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced it will effect...
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) portfolio, including α4b7 and TL1A programs Sale of legacy pipeline candidate, pegzilarginase, further streamlines operations and increases...
Polar Capital Holdings Plc Enters Stake in Aeglea BioTherapeutics Inc
On July 19, 2023, Polar Capital Holdings Plc (Trades, Portfolio), a London-based investment firm, made a significant move in the biotechnology sector by investing in 3,936,198 shares in Aeglea BioTherapeutics Inc. This transaction marked a 10000.00% change in the firm's...
Source: https://incomestatements.info
Category: Stock Reports